Zotepine versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Dickenson, Rebecca ^a   Fenton, Mark ^b  

^a NOTTINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016287939     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010644     Document Type: Article

References (34)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
3. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
4. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
5. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
6. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971-80.
7. Drugs Information Online. http://www.drugs.com/international/zotepine.html Accessed on 17.10.2012.
8. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
9. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
10. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
11. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(1):876-83.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
13. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
14. Hutton Jane L. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
15. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. http://apps.who.int/classifications/icd10/browse/2010/en#/F20-F29 2010.
16. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
17. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
18. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
19. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
20. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
21. Messias E, Chen CY, Eaton WW. Epidemiology of Schizophrenia: Review of Findings and Myths. The Psychiatric clinics of North America 2007;30(3):323-38. [PUBMED: 17720026]
22. National Electronic Library for Medicines. http://www.nelm.nhs.uk/en/NeLM-Area/News/2010---August/18/Discontinuation-of-zotepine-Zoleptil-from-the-UK-market/ Accessed on 17.10.2012.
23. National Institute of Mental Health. http://www.nimh.nih.gov/health/publications/schizophrenia/complete-index.shtml Accessed 17.10.2012.
24. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
25. Peluso MJ, Lewis SW, Barnes TRE, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. British Journal of Psychiatry 2012;200:387-92.
26. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
27. Stephen M. Stahl. Stahl's Essential Psychopharmacology. 3rd Edition. Cambridge University Press, 2008.
28. Subramanian S, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, et al.Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: ]
29. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
30. World Health Organization. Schizophrenia. http://www.who.int/mental_health/management/schizophrenia/en/.
31. Wiersma D, Nienhuis FJ, Sloof CJ, Giel R. Natural ccourse of schizophrenic ddisorders: a 15-year ffollow up of a Dutch incidence cohort. Schizophrenia Bulletin 1998;24(1):75-85.
32. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
33. DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: ]
34. Fenton M, Morris S, De-Silva P, Bagnall A, Cooper SJ, Gammelin G, et al.Zotepine for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: ]